GLP-1 pioneers DiMarchi/Tschöp propose non-GLP-1 obesity approach; ESCMID Global opens in Munich; Circle Pharma macrocyclic peptide data at AACR; Scientific American on the peptide craze.
Read digest →AACR 2026 opens with peptide cancer therapies in the spotlight; CAMPER AI-designed peptides kill MRSA persisters; Novo partners with OpenAI for drug discovery.
Read digest →Lilly's Foundayo ACHIEVE-4 data eases FDA concerns with 57% lower death risk; FDA peptide panelists expected to support broader access; non-GLP-1 peptide pipeline advances.
Read digest →FDA schedules July advisory panel on BPC-157 and 6+ peptides for compounding; Hims surges 12%; fewer than 1 in 4 GLP-1 patients stay on treatment after a year.
Read digest →FDA requests Foundayo post-market liver and heart data; Australia's TGA warns on unapproved peptides; PEPITEM matches infliximab for arthritis; AI discovers novel antimicrobials.
Read digest →Stanford discovers brain-targeted peptide rivaling Ozempic without side effects; CNN publishes comprehensive peptide guide; tirzepatide outperforms semaglutide at 12 months.
Read digest →ProPublica investigates risks of FDA peptide reclassification; semaglutide shows mixed results in depression trial; Noom acquires compounding pharmacy to enter peptide market.
Read digest →Apotex wins first generic semaglutide approval, retatrutide aces Phase III, and the Foundayo vs oral Wegovy rivalry intensifies.
Read digest →Lilly launches Foundayo with $1.5B pre-stocked; FDA escalates compounding crackdown; Merck oral peptide PCSK9 inhibitor impresses; Reddit study reveals GLP-1 side effects.
Read digest →Health Canada warns against unauthorized peptides; Nature GWAS links GLP1R variants to weight loss; Indian generic semaglutide surges past Mounjaro.
Read digest →FDA finds no suicide risk with GLP-1s, oral Wegovy draws explosive demand, Lilly's Foundayo launches at $25/month, and a Utah physician is indicted for importing peptides.
Read digest →Landmark GLP-1 pricing drops to $245/mo, Lilly's retatrutide aces Phase 3, and investigations expose peptide quality failures and safety risks.
Read digest →Pinnacle raises $89M for oral peptides matching biologics, cagrilintide shows Phase 3 obesity results, and higher-dose Wegovy achieves 21% weight loss.
Read digest →UK MHRA investigates peptide clinics, GoodRx matches oral semaglutide pricing, FDA approves Eli Lilly oral GLP-1, and India tightens GLP-1 oversight.
Read digest →RFK Jr. moves to reverse FDA peptide ban amid safety pushback; Lilly retatrutide hits Phase 3 endpoints; oral semaglutide may outperform orforglipron.
Read digest →Eli Lilly's oral GLP-1 Foundayo approved in record time; retatrutide hits 28.7% weight loss in Phase 3; semaglutide linked to rare skin condition.
Read digest →FDA approves Eli Lilly's Foundayo, the first small-molecule GLP-1 pill for obesity. GLP-1 drugs show heart and kidney benefits in Type 1 diabetes.
Read digest →FDA expected to lift peptide compounding ban at RFK Jr.'s urging; 30 telehealth firms warned; Novo slashes Ozempic prices in India; UK expands Wegovy prescribing.
Read digest →